In our latest episode, we delve into the world of space medicine to explore how drug crystallization in microgravity could revolutionize biologic drug administration. Joining us is Dr Katie King, CEO of BioOrbit, to discuss the science, challenges, and technological advancements that could make space-based drug production a reality.
At this year’s European Society for Blood and Marrow Transplantation (EBMT) meeting in Glasgow, Scotland, graft-versus-host disease (GVHD) emerged as a central topic of discussion. The conference featured a wealth of innovative research, with numerous abstracts presenting advances in the management of chronic and refractory GVHD, offering new hope for patients facing this challenging complication. Here we explore some of the most exciting abstracts presented.
A new study published in the Journal of Radiology reveals promising advancements in the use of artificial intelligence (AI) to improve radiology reporting, particularly in the context of prostate cancer detection. The research demonstrates that AI can significantly enhance the accuracy and efficiency of radiological assessments, especially in complex cases involving large sets of imaging data.
Colorectal cancer is the third most common cancer worldwide and is the second leading cause of cancer-related deaths for men and women combined. The disease is on the rise in younger generations. It is the leading cause of cancer-related deaths in men under 50, and researchers predict it will become the leading cause in men and women ages 20-49 within the next decade. However, it remains less known and less funded than other cancers. For comparison, breast cancer, which has benefited greatly from major funding that contributed to significant research advancements, has a five-year survival rate of 30%, whereas the five-year survival rate for colorectal cancer is drastically lower at only 13%. To achieve better outcomes, the Colorectal Cancer Alliance (Alliance) is reinvigorating its mission to end colorectal cancer with the launch of Project Cure CRC.
Few alliances have impacted patient care as significantly as the Myeloproliferative Neoplasms Research Consortium (MPN-RC). Established in 2006, the MPN-RC is an international group dedicated to advancing research and developing innovative treatment strategies for myeloproliferative neoplasms. In this episode, we speak with Prof. John Mascarenhas, about the coalition's founding, operational mechanics and how their efforts have led to paradigm-shifting therapies in the field.
Select a discussion in the hub to watch our multidisciplinary team share expert perspectives on the appropriate implementation of immune checkpoint inhibitors through shared decision making to ensure optimal outcomes for patients with endometrial cancer.
Watch leading experts Shaji Kumar and Rahma Warsame discuss the current and evolving treatment landscape in relapsed/refractory multiple myeloma, as well as key factors influencing treatment decisions.
Experts answer questions with in-depth advice on the current clinical landscape and how new guidelines might impact regional clinical practice. Useful tips below will show how to navigate the activity.
Experts in the management of lung cancer discuss emerging antibody-drug conjugates for the treatment of patients with non-small cell lung cancer (NSCLC)
Three experts consider unmet needs in chronic myeloid leukaemia and how new and emerging treatments may help address them.
Join Dr Elizabeth Smyth as she highlights the latest clinical data on the use of immunotherapy in the management of esophageal squamous cell carcinoma (ESCC).
Watch this two-part activity exploring the latest data on the use of PARP inhibitors in first-line maintenance therapy in ovarian cancer. Filmed following the ESGO European Congress on Gynaecological Oncology 2022. Part 1: Watch gynaecological cancer expert Prof. Jonathan Ledermann review key data from ESGO 2022 Watch Now Part 2: Watch leading experts consider what these data may mean for global and regional practice Select An Interview
Watch a leading haematologist, a primary care physician and a patient with paroxysmal nocturnal haemoglobinuria (PNH) share their perspectives on the clinical challenges associated with PNH.
Two specialists in chronic myeloid leukaemia (CML) discuss the mechanisms of action and latest data for current and emerging treatments and how they may impact the management of CML after two prior lines of therapy.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.